Article and Video CATEGORIES
We are in the midst of a remarkable transitional time in cancer care that is exciting but challenging, since we now have patients divided into smaller and smaller groups based on molecular markers. Along with that, more and more patients and caregivers are participating in social media and online discussion groups. What are the implications for these changes, and how can we use them to accelerate the pace of clinical research? I'd like to focus on a couple of key questions for our next lung cancer tweetchat on September 26, at 8 PM Eastern, 5 PM Pacific.
1) What are leading barriers to clinical research? Which ones might be addressed by connecting members of the lung cancer community online?
2) Can patients & caregivers share data, e.g., Patients Like Me, to facilitate better understanding & generate more interest from pharma companies in studying lung cancer patient groups (potentially narrow ones like those with ROS-1 rearrangements)?
3) Can we lower barriers by making it easier for patients to learn about & travel to participate in trials? Share air miles to help people travel for trials? Offer housing as a network? Telemedicine visits to minimize travel?
I sincerely hope we haven't reached the pinnacle of our efficiency in cancer research, because it's a frustratingly, even maddeningly slow process. So what other ideas do you have? Your ideas could lead to a faster pace for the trials that lead to new treatments in lung cancer.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…